HOME >> BIOLOGY >> NEWS
Weill Cornell team identifies potential new cancer drug target

NEW YORK (June 20, 2007) -- Research led by scientists at Weill Cornell Medical College has uncovered two new potential points of vulnerability on a key cancer-promoting protein, called XIAP. Drugs that target either of these activities could help push cancer cells back into a more regular programmed cell death and thereby reduce or eliminate tumors.

These findings were published in the June 8 issue of Molecular Cell by Dr. Hao Wu, a professor in the Department of Biochemistry of Weill Cornell, and her team.

Experts know that cancers spread in two separate ways -- by the uncontrolled proliferation of cells, and by their refusal to undergo normal, healthy, programmed cell death, or "apoptosis."

In many cancers, dysfunction in a biochemical cascade called the NF-kappa B pathway causes tumor cells to sidestep apoptosis and become dangerously immortal.

"So, drug development aimed at short-circuiting NF-kappa B has become very hot in the past few years," Dr. Wu says.

Her team focused on a particular protein involved in the NF-kappa B pathway called the "X-linked inhibitor of apoptosis" (XIAP). Scientists had already discovered that XIAP thwarts the apoptotic impulse by putting the brakes on key enzymes called caspases. XIAP is also known to be highly active in cancer cells, but it is found in relatively low levels in healthy cells. How XIAP inhibits caspases is known, but how XIAP induces NF-kappa B activation is entirely unclear.

"We wondered if we could find out how XIAP induces the NF-kappa B pathway," explains lead researcher Dr. Miao Lu, a postdoctoral fellow of biochemistry at Weill Cornell.

In their experiments, the researchers used a variety of cutting-edge techniques, including X-ray crystallography, to track changes in the structure and activity of XIAP and the molecules it interacts with in cells.

"We discovered that XIAP interacts with the NF-kappa B cycle in two distinct wa
'"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
21-Jun-2007


Page: 1 2

Related biology news :

1. Weill Cornell pharmacologist receives prestigious NIH MERIT Award
2. Stem cell research at Weill Cornell, The Rockefeller University, and Sloan-Kettering
3. Weill Cornell team develops fast-acting anthrax vaccine
4. Cornell scientists link E. coli bacteria to Crohns disease
5. Methodist, University of Houston, Cornell combine biomedical imaging expertise
6. Cornell lab confirms deadly fish virus spreading to new species
7. NSF awards $3.3 million grant to Cornell to bolster the percentage of women faculty members
8. Cornell researchers find serious fish virus in Northeast for first time
9. Cornell finds natural selection in humans
10. Northeast Sun Grant Institute at Cornell spurs green revolution
11. Cornell graduate student named 2005 AIBS Emerging Public Policy Leader

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... , ... August 05, 2020 , ... Regenative Labs has ... new innovations, CoreText™ and ProText™, making them the first Wharton’s jelly allografts to be ... a syringe. The company’s solutions are the first Wharton’s jelly allograft product to be ...
(Date:7/22/2020)... ... July 21, 2020 , ... ... and innovation in technology and compliance, announces a new solution to manage regulated ... ensure every layer of their technology stack complies with FDA and global regulations. ...
(Date:7/10/2020)... ... ... Today CJ BIO announced the first in a series of Food Ingredient MasterClass ... is revolutionizing ingredient mixes, nutritional content and flavor profiles across a range of savory ... at11:00 AM (CDT) during SHIFT20, the virtual edition of the IFT Annual Meeting & ...
Breaking Biology News(10 mins):
(Date:8/3/2020)... ... August 03, 2020 , ... Introducing Ardent Animal Health – MediVet Biologics ... , Known as MediVet Biologics since its formation in 2016, the company ... Ardent Animal Health will build on its base of innovative therapies for osteoarthritis and ...
(Date:7/31/2020)... ... 2020 , ... Anomet Products has introduced new custom composite ... with CRM, neurostimulation, vascular, and related devices. , Anomet Medical Clad Wire ... and cost criteria; especially where solid wire is limited. Typical configurations for implantable ...
(Date:7/31/2020)... ... July 30, 2020 , ... ... the life sciences industry, today announced the release of its signature product ... Medical Science Liaisons (MSLs) and other field medical professionals. , Beacon ...
(Date:7/18/2020)... ... July 16, 2020 , ... Medial EarlySign , a ... prevention of high-burden diseases, and Centric Consulting, a business and technology consulting firm, ... existing data in order to identify and prioritize patients for care. , Combining ...
Breaking Biology Technology:
Cached News: